Mytos, a biotechnology company automating cell manufacturing, StemSight and two other cell therapy developers announced collaborations aiming to increase the scalability and cost-efficiency of cell therapy manufacturing. The announcement was covered by Endpoint News.

StemSight's CEO Laura Koivusalo interviewed by Blake Forman for  Technology Networks article. The news piece nicely captures StemSight's groundbreaking work in aiming to cure blindness with stem cells.

StemSight welcomes Maarit Merla to StemSight’s Board of Directors!
Maarit is the CEO of the Finnish Drug Discovery Center Ltd. and brings nearly 25 years of leadership experience across biotech, pharma, and medtech. Her track record includes raising €9M in funding, leading strategic partnerships like Forendo Pharma’s collaboration with Novartis, and playing a key role in the company’s acquisition by Organon.

Our CEO Laura has been awarded the title of Research Entrepreneur of the Year by the Finnish Science Foundation for Economics and Technology (KAUTE Foundation). The award is a recognition for Laura's persistent work and bold choices in building StemSight. You can read the full post and Laura's interview on the KAUTE foundation's website.